CJC-1295 ipamorelin combines two peptides that stimulate growth hormone release through different pathways. It attracts interest for muscle growth, fat loss, recovery, and sleep—but understanding the research takes more than reading a list of advertised benefits.
Human studies have measured hormone responses to each ingredient individually. What remains less clear is whether a particular combination produces meaningful, lasting improvements in the outcomes people want.[1][2]
Three points matter before comparing products:
- Formulation matters: CJC-1295 with DAC differs from products sold as “without DAC.”
- Hormonal changes and physical results are different outcomes.
- Vial strength does not establish an effective or safe dosage.
What Is CJC-1295 Ipamorelin?
CJC-1295 is an analog of growth hormone-releasing hormone, or GHRH. Ipamorelin is a growth hormone secretagogue, a substance that encourages GH release, acting through the ghrelin receptor system. Both target the body’s hormone signaling rather than supplying manufactured GH directly.[3][4][5]
| Ingredient | Main role | Research distinction |
|---|---|---|
| CJC-1295 | Stimulates the GHRH receptor pathway | Landmark human research used the long-acting preparation |
| Ipamorelin | Stimulates the ghrelin receptor pathway | Human studies include intravenous administration |
A CJC-1295 ipamorelin stack means using the compounds together. A blend generally means both are supplied in one preparation. The combination name alone does not establish the amount of each ingredient or which CJC preparation it contains.
This is also different from HGH replacement. Somatropin products contain recombinant human growth hormone and have specific approved indications, including appropriately diagnosed adult GH deficiency.[6]
CJC-1295 With DAC vs. Without DAC
DAC refers to the modification that enables CJC-1295 to bind to albumin, a circulating blood protein. This prolongs its presence in the body. The development research examined this albumin-binding strategy directly.[3]
Products labeled “CJC-1295 without DAC” are commonly associated with modified GRF (1–29), which lacks that extension. FDA treats CJC-1295 and CJC-1295 DAC as distinct active substances that are not interchangeable. Check the actual compound rather than relying on a shortened product name.[7]
In the principal human CJC-1295 study, the estimated half-life was approximately 5.8–8.1 days. That figure applies to the studied long-acting preparation.[1]
Longer exposure also does not mean that GH pulses disappear. A separate human study found preserved pulsatility alongside higher background GH levels after CJC-1295 administration.[8]
The practical implication: a study of long-acting CJC-1295 cannot automatically validate a short-acting blend’s frequency, dose, or results.
How Do CJC-1295 and Ipamorelin Work Together?
The rationale is to stimulate GH release through complementary receptor pathways. Research involving GHRH and other GH-releasing peptides shows that combining these signals can produce a substantial GH response.
For example, a study of 47 men examined GHRH plus GHRP-2 under experimentally controlled sex-hormone conditions. Responses varied with factors including abdominal visceral fat and IGF-1. This helps explain interest in combining secretagogues, but it studied different agents from CJC-1295 and ipamorelin.[9]
Accordingly, “synergy” describes a research rationale here; it does not supply a proven multiplier for muscle growth or fat loss from a commercial blend.
Ipamorelin’s reputation for selectivity also comes partly from animal experiments. In swine, it stimulated GH without the ACTH and cortisol increases observed with some comparison peptides. Those findings do not establish that it has no other hormonal effects in every person.[4]
CJC-1295 Ipamorelin Benefits: What Does Research Show?
The most useful approach is to separate measured hormone effects from proposed improvements in appearance, performance, and well-being.
Growth Hormone and IGF-1 Responses
The clearest direct human findings concern hormone measurements. In two randomized, placebo-controlled trials involving healthy adults, long-acting CJC-1295 increased mean GH and IGF-1. After a single injection, elevated mean GH persisted for at least six days and IGF-1 for approximately nine to eleven days.[1]
A separate study gave healthy male volunteers intravenous ipamorelin infusions and measured a distinct episode of GH release.[2]
These findings demonstrate biological activity. They do not tell us how much muscle someone will gain or how much better they will sleep on the combination.
IGF-1 is useful because it stays more stable during the day than GH. Its interpretation depends on factors such as age and medical context; a higher result is not automatically a better health outcome.[10]
Normal adult hormone levels also change with age. A result below a young adult’s level does not automatically identify a disorder needing treatment; the laboratory’s reference range and the person’s clinical circumstances matter.[10]
Muscle Growth, Strength, and Exercise Recovery
Interest in CJC-1295 ipamorelin muscle growth comes from GH’s involvement in tissue metabolism. However, “lean mass,” “muscle,” and “strength” are not interchangeable measurements.
In a randomized study of 16 young men undertaking resistance training, added GH increased fat-free mass and total body water more than placebo. It did not produce greater improvements in measured muscle strength, muscle protein synthesis, or muscle size.[11]
That study tested GH itself, so it cannot settle the effectiveness of the peptide blend. It does show why an increase in fat-free mass should not automatically be described as new functional muscle.
The individual-peptide trials cited here do not establish faster workout recovery, tendon healing, or improved athletic performance from the combination. Those claims require studies measuring those outcomes directly.
Fat Loss and Body Composition
GH has effects on fat metabolism, but increasing GH release does not guarantee weight loss. In one mouse study, ipamorelin increased relative body fat; the researchers identified effects that could occur independently of GH, including increased feeding.[12]
This animal finding does not predict weight gain in humans. It does challenge the assumption that every GH secretagogue must function as a fat-loss treatment.
For CJC-1295 ipamorelin weight loss, the reviewed evidence does not establish a dependable amount of fat loss or a successful maintenance strategy. Approved obesity treatments have their own indications and supporting trials, as summarized by NIDDK.[13]
Readers comparing related compounds can also see our tesamorelin review. Evidence for another peptide should be evaluated separately before drawing conclusions about this combination.
Sleep, Energy, and Healthy Aging
There is human research connecting GHRH administration with sleep changes. In a small crossover study involving 23 men, intranasal GHRH increased aspects of slow-wave and REM sleep, particularly later in the night.[14]
The study used a different preparation and route, so it cannot establish that injected CJC-1295 ipamorelin improves sleep quality or daytime energy.
Likewise, the cited combination-related rationale does not establish wrinkle reduction, reversal of aging, or restored youthful performance. Our guide to peptides for anti-aging provides broader context for comparing these claims.
Persistent fatigue deserves assessment on its own merits. GH-deficiency testing involves clinical interpretation and may require stimulation testing; symptoms alone do not establish the diagnosis.[15]
CJC-1295 Ipamorelin Dosage: Formulations and Evidence
The reviewed research does not establish a standard safe and effective CJC-1295 ipamorelin dosage for muscle growth, weight loss, or anti-aging.
Published research doses belong to specific experiments. For example, the CJC-1295 pulsatility study examined single injections of 60 or 90 micrograms per kilogram in healthy men. An ipamorelin trial used 0.03 milligrams per kilogram intravenously twice daily in patients recovering from bowel surgery.[8][5]
Those methods are study descriptions, not a dosing schedule for the combination. They differ in compound, preparation, route, population, and purpose.
To understand a product label, distinguish these terms:
| Label term | Meaning |
|---|---|
| Vial content | Total amount supplied before dilution |
| Ingredient amount | Quantity of each individual peptide |
| Concentration | Amount of peptide per milliliter of solution |
| Administered dose | Amount of each peptide delivered in the measured volume |
For example, a vial labeled 5 mg CJC-1295 plus 5 mg ipamorelin contains 10 mg total, with 5 mg of each ingredient. It does not contain 10 mg of each, and the label does not mean the entire vial is one dose.
Also, 1 mg equals 1,000 micrograms. Confusing those units creates a thousandfold error.
Syringe markings describe volume on a particular device; the peptide amount also depends on concentration. Instructions expressed only as “units” cannot be transferred reliably between products.
A fixed-ratio blend changes exposure to both ingredients together when its administered volume changes. Accurate arithmetic cannot establish an appropriate frequency, cycle length, or clinical benefit. Fasting and bedtime schedules likewise require evidence beyond a plausible hormone-signaling explanation.
CJC-1295 Ipamorelin Side Effects and Safety
Safety information comes from several different sources, which should not be collapsed into one supposedly proven side-effect profile.
The CJC-1295 trials reported no serious adverse reactions during their short follow-up. That finding is reassuring within those trials, but it does not resolve longer-term or combination risks.[1]
- CJC-1295-specific concerns: FDA identifies increased heart rate and systemic vasodilatory reactions among associated serious adverse events.
- Ipamorelin-specific uncertainty: FDA notes serious adverse events, including death, in an intravenous gastric-motility study. Its detailed review says the relationship between two deaths and ipamorelin was unclear. This does not quantify risk with other routes.[16]
- Preparation concerns: FDA highlights potential immune reactions, peptide-related impurities, and limited safety information for these substances.[17]
The published postoperative ipamorelin trial described short-term treatment as well tolerated, but found no statistically significant improvement in its main meal-tolerance outcome. A brief surgical trial cannot establish long-term wellness safety.[5]
Broader GH treatment experience raises additional considerations. Somatropin labeling describes fluid retention, joint or muscle discomfort, nerve-compression symptoms, and impaired glucose tolerance. These are findings for somatropin, not measured side-effect frequencies for this blend.[6]
FDA’s ipamorelin review also found insufficient evidence to rule out related concerns, including glucose intolerance and diabetes. Stimulating the body’s own hormone release does not automatically eliminate hormone-related risks.[16]
This distinction also matters when discussing existing diabetes, pituitary disease, other medications, pregnancy, or breastfeeding with a qualified clinician. A generalized online protocol cannot resolve individual suitability.
Finally, compounded drugs are not FDA-approved and do not undergo FDA premarket evaluation of safety, effectiveness, and quality. Contamination or incorrect ingredient amounts can create additional risks.[18]
A purity percentage or certificate of analysis does not establish that repeated administration of the complete preparation is effective or safe. Quality testing and clinical evidence answer different questions.
CJC-1295 Ipamorelin Results: How Long Does It Take?
Hormone responses can be measured on a much shorter timescale than changes in strength, body composition, or sleep. Neither that response nor a study’s follow-up period establishes when a user should expect visible results.
The reviewed trials do not validate a universal “results by week four” timeline for the combination. Before-and-after photographs also cannot isolate its contribution when diet, training, lighting, hydration, and other treatments change simultaneously.
Meaningful results require clearly defined outcomes and appropriate comparison groups—not simply a higher laboratory value.
Frequently Asked Questions
Is CJC-1295 Ipamorelin FDA-Approved?
No. CJC-1295 and ipamorelin are not components of FDA-approved drugs. A compounded preparation does not become FDA-approved because a clinician prescribes it; FDA specifically identifies safety and evidence concerns involving these substances.[7][16][18]
Is It the Same as HGH?
No. HGH products such as somatropin supply growth hormone directly. CJC-1295 and ipamorelin stimulate hormone-release pathways. That distinction describes their mechanisms; it does not, by itself, prove that the combination is safer or equally effective.[6]
Does CJC-1295 Ipamorelin Increase Testosterone?
The human ingredient studies discussed above investigated GH-related responses, not an established treatment for low testosterone. Changes in one hormone pathway should not be assumed to correct another. The evidence presented here does not validate the blend as testosterone replacement.[1][2]
What Does a 5 mg/5 mg Blend Label Mean?
It indicates 5 mg of each listed ingredient, totaling 10 mg in the vial. Concentration depends on the preparation’s volume. Neither the combined total nor the ratio establishes how much should be administered.
Should It Be Taken on an Empty Stomach?
The reviewed evidence does not establish a universal fasting interval for this combination. Physiological explanations and schedules used by clinics or sellers are not equivalent to trials demonstrating that a particular interval improves meaningful outcomes.
Conclusion
CJC-1295 ipamorelin has a plausible rationale for stimulating GH release, supported by human studies of the individual ingredients. The larger questions concern what the exact combination delivers in muscle growth, fat loss, sleep, and long-term safety.
Evaluate the preparation, study population, measured outcome, and dosing evidence together. That approach provides a more useful basis for understanding the blend than assuming that a stronger hormone response guarantees better health or performance.
References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799. doi:10.1210/jc.2005-1536. ↩
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412. doi:10.1023/a:1018955126402. ↩
- Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052. doi:10.1210/en.2004-1286. ↩
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552. doi:10.1530/eje.0.1390552. ↩
- Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527. doi:10.1007/s00384-014-2030-8. ↩
- Pfizer. GENOTROPIN (somatropin): Prescribing Information. DailyMed, National Library of Medicine. Revised July 2026. Accessed September 13, 2026. ↩
- U.S. Food and Drug Administration. CJC-1295-Related Bulk Drug Substances: FDA Briefing Document. Pharmacy Compounding Advisory Committee meeting. December 4, 2024. Accessed September 13, 2026. ↩
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792. doi:10.1210/jc.2006-1702. ↩
- Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009;296(5):E1085. doi:10.1152/ajpendo.91001.2008. ↩
- MedlinePlus, National Library of Medicine. IGF-1 (Insulin-like Growth Factor 1) Test. Accessed September 13, 2026. ↩
- Yarasheski KE, Campbell JA, Smith K, Rennie MJ, Holloszy JO, Bier DM. Effect of growth hormone and resistance exercise on muscle growth in young men. Am J Physiol. 1992;262(3 Pt 1):E261. doi:10.1152/ajpendo.1992.262.3.E261. ↩
- Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001;280(1):132. doi:10.1006/bbrc.2000.4065. ↩
- National Institute of Diabetes and Digestive and Kidney Diseases, NIH. Prescription Medications to Treat Overweight & Obesity. Accessed September 13, 2026. ↩
- Perras B, Marshall L, Köhler G, Born J, Fehm HL. Sleep and endocrine changes after intranasal administration of growth hormone-releasing hormone in young and aged humans. Psychoneuroendocrinology. 1999;24(7):743. doi:10.1016/s0306-4530(99)00027-x. ↩
- MedlinePlus, National Library of Medicine. Growth Hormone Tests. Accessed September 13, 2026. ↩
- U.S. Food and Drug Administration. Ipamorelin-Related Bulk Drug Substances: FDA Briefing Document. Pharmacy Compounding Advisory Committee meeting. October 29, 2024. Accessed September 13, 2026. ↩
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Accessed September 13, 2026. ↩
- U.S. Food and Drug Administration. Understanding the Risks of Compounded Drugs. Accessed September 13, 2026. ↩
